This week the National Institutes of Health awarded a $2.3 million grant to The New York Blood Center’s (NYBC), one of the largest independent, community-based blood centers in the country, to study potential solutions to abnormal immunologic responses to blood transfusions in patients with sickle cell disease (SCD). The…
A new research study has determined that body measurements (anthropometric variables) of children with sickle cell anemia are usually smaller than healthy children. The research study, “Body mass index and other anthropometric variables in children with sickle cell anemia,” was published in Pakistan Journal of Medical Sciences. Sickle…
A study by researchers at the Hospital for Sick Children, Toronto reveals that the drug hydroxyurea can benefit children with sickle cell (SC) disease related lung problems. The study, “Effect of Hydroxyurea on Pulmonary Function Decline in Children with Sickle Cell Disease,” was presented at the ATS 2016 International…
A group of interdisciplinary researchers from universities and medical colleges in Lagos, Nigeria, recently published a study in the Italian Journal of Pediatrics that has significant public health implications on treating children with sickle cell anemia (SCA) in the developing world. The study, “…
A recently published study in the Journal of Clinical Investigation identified an association between worsening intravascular hemolysis (rupture or destruction of red blood cells) and the rapid clinical deterioration seen during adult transition in Sickle cell disease (SCD). The study, “Nonhematopoietic Nrf2 dominantly…
Sickle cell anemia (SCA), one of the most common hemoglobinopathies, is caused by a mutation in the β-globin gene. In a new research study, the hemorheological and hematological parameters in men suffering from SCA and priapism — a persistent and potentially painful state of penile erection — were investigated.
A study performed by researchers at Baskent University, in Ankara, Turkey, found that mutations in certain genes play a role in the deposition of iron in the liver of patients with sickle cell (SC) disease. Findings, presented in the study “Effect of Hereditary Hemochromatosis Gene (HFE)…
Acetylon Pharmaceuticals recently published the outcomes of its preclinical data concerning the mechanism of action of its selective inhibition based treatment of sickle cell (SC) disease/beta-thalassemia (BT). These findings, “Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2,” were published in…
Get regular updates to your inbox.